Literature DB >> 18606107

Management of post-subarachnoid hemorrhage vasospasm.

William Gump, Daniel T Laskowitz.   

Abstract

Permanent neurologic injury and death remain common outcomes following aneurysmal subarachnoid hemorrhage. Although many sophisticated techniques are evolving for securing intracranial aneurysms to prevent rebleeding, progress is lagging in the management of posthemorrhagic complications, particularly cerebral vasospasm. Vasospasm can be defined either angiographically, by visible reduction in arterial lumen diameters, or clinically, with signs of focal or regional cerebral ischemia. The relationship between angiographic and clinical vasospasm is not straightforward. The most important known risk factors for developing posthemorrhagic vasospasm include volume and distribution of subarachnoid blood, and no preventive measures have proven effective. Established treatment strategies for vasospasm include hyperdynamic therapy, angioplasty, and selective intra-arterial injection of vasodilators. The vasodilatory approach has been called into question by recent data suggesting that reduction of arterial luminal diameters may be due largely to a proliferative arteriopathy. Novel treatment strategies have focused on protecting the cerebrum, targeting components of the inflammatory cascade, and identifying genetic factors predisposing toward vasospasm, all of which may soon yield new treatment modalities.

Entities:  

Mesh:

Year:  2008        PMID: 18606107     DOI: 10.1007/s11883-008-0054-7

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  53 in total

1.  Surgical risk as related to time of intervention in the repair of intracranial aneurysms.

Authors:  W E Hunt; R M Hess
Journal:  J Neurosurg       Date:  1968-01       Impact factor: 5.115

2.  Monoclonal antibody against E selectin attenuates subarachnoid hemorrhage-induced cerebral vasospasm.

Authors:  Chih-Lung Lin; Aaron S Dumont; Tarkan Calisaneller; Aij-Lie Kwan; Shen-Long Hwong; Kevin S Lee
Journal:  Surg Neurol       Date:  2005-09

3.  Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study.

Authors:  Peter Vajkoczy; Bernhard Meyer; Stefan Weidauer; Andreas Raabe; Claudius Thome; Florian Ringel; Volker Breu; Peter Schmiedek
Journal:  J Neurosurg       Date:  2005-07       Impact factor: 5.115

4.  Role of c-Jun N-terminal kinase in cerebral vasospasm after experimental subarachnoid hemorrhage.

Authors:  Hiroshi Yatsushige; Mitsuo Yamaguchi; Changman Zhou; John W Calvert; John H Zhang
Journal:  Stroke       Date:  2005-06-09       Impact factor: 7.914

5.  Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm.

Authors:  Neeraj Badjatia; Mehmet A Topcuoglu; Johnny C Pryor; James D Rabinov; Christopher S Ogilvy; Bob S Carter; Guy A Rordorf
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

Review 6.  Cardiac manifestations after subarachnoid hemorrhage: a systematic review of the literature.

Authors:  Yasser L Sakr; Issam Ghosn; Jean Louis Vincent
Journal:  Prog Cardiovasc Dis       Date:  2002 Jul-Aug       Impact factor: 8.194

7.  Meta-analysis of APOE genotype and subarachnoid hemorrhage: clinical outcome and delayed ischemia.

Authors:  L A Lanterna; Y Ruigrok; S Alexander; J Tang; F Biroli; L T Dunn; W S Poon
Journal:  Neurology       Date:  2007-08-21       Impact factor: 9.910

8.  Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage.

Authors:  G S Allen; H S Ahn; T J Preziosi; R Battye; S C Boone; S C Boone; S N Chou; D L Kelly; B K Weir; R A Crabbe; P J Lavik; S B Rosenbloom; F C Dorsey; C R Ingram; D E Mellits; L A Bertsch; D P Boisvert; M B Hundley; R K Johnson; J A Strom; C R Transou
Journal:  N Engl J Med       Date:  1983-03-17       Impact factor: 91.245

9.  Reduced endothelial NO-cGMP-mediated vascular relaxation and hypertension in IL-6-infused pregnant rats.

Authors:  Julia M Orshal; Raouf A Khalil
Journal:  Hypertension       Date:  2004-01-05       Impact factor: 10.190

Review 10.  Role of transcranial Doppler in neurocritical care.

Authors:  Maher Saqqur; David Zygun; Andrew Demchuk
Journal:  Crit Care Med       Date:  2007-05       Impact factor: 7.598

View more
  2 in total

Review 1.  Neurovascular events after subarachnoid hemorrhage: focusing on subcellular organelles.

Authors:  Sheng Chen; Haijian Wu; Jiping Tang; Jianmin Zhang; John H Zhang
Journal:  Acta Neurochir Suppl       Date:  2015

2.  pH-sensitive NMDA inhibitors improve outcome in a murine model of SAH.

Authors:  Haichen Wang; Michael L James; Talaignair N Venkatraman; Lawrence J Wilson; Polina Lyuboslavsky; Scott J Myers; Christopher D Lascola; Daniel T Laskowitz
Journal:  Neurocrit Care       Date:  2014-02       Impact factor: 3.210

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.